Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 4:23:1204-1216.
doi: 10.1016/j.omtn.2021.01.030. eCollection 2021 Mar 5.

Plasmid encoding microRNA-200c ameliorates periodontitis and systemic inflammation in obese mice

Tadkamol Krongbaramee  1 , Min Zhu  1 , Qingwen Qian  2 , Zeyuan Zhang  2 , Steven Eliason  3 , Yi Shu  1 , Fang Qian  1 , Adil Akkouch  1 , Dan Su  3 , Brad A Amendt  1   3   4 , Ling Yang  2 , Liu Hong  1   4
Affiliations

Plasmid encoding microRNA-200c ameliorates periodontitis and systemic inflammation in obese mice

Tadkamol Krongbaramee et al. Mol Ther Nucleic Acids. .

Abstract

The present study was conducted to characterize microRNA-200c (miR-200c) and its regulators in adipogenic differentiation, obesity, and periodontitis in obese subjects (PiOSs), and to determine the therapeutic efficacy of plasmid DNA encoding miR-200c as a treatment for PiOSs. We report that highly expressed miR-200c in gingival tissues was downregulated in diet-induced obese (DIO) mice and during adipogenic differentiation of human bone marrow mesenchymal stromal cells (hBMSCs). Local injection of Porphyromonas gingivalis lipopolysaccharide (Pg-LPS) in the maxilla interdental gingiva of DIO mice reduced miR-200c in gingival and adipose tissues and induced periodontal inflammation associated with systemic elevation of interleukin-6 (IL-6) and impaired glucose tolerance. The inhibitory functions of Pg-LPS and IL-6 on miR-200c and their effectiveness on Zeb1 were confirmed in vitro. Injection of naked plasmid DNA encoding miR-200c into the gingiva effectively rescued miR-200c downregulation, prevented periodontal and systemic inflammation, and alleviated the impaired glucose metabolism in obese mice with LPS-induced periodontitis. Increased circulating exosomal miR-200c and its function on suppressing proinflammatory cytokines and adipogenesis explained the mechanism(s) of gingival application of miR-200c in attenuating systemic inflammation in PiOSs. These results demonstrated that miR-200c reduced by Pg-LPS and IL-6 in periodontitis and obesity might lead to the pathogenesis of PiOSs, and upregulation of miR-200c in the gingiva presents a therapeutic approach for PiOSs.

Keywords: IL-6; Leptin; Pg-LPS; Zeb1; gene therapy; glucose intolerance; microRNA-200c; mouse; obesity; periodontitis.

PubMed Disclaimer

Conflict of interest statement

L.H. and B.A.A. have a US patent for miR-200c-based bone regeneration. B.A.A. is the founder of the NaturemiRI Company.

Figures

None
Graphical abstract
Figure 1
Figure 1
Relative fold changes of miR-200c expression in different tissues and organs of 22-week-old C57BL/6J mice ∗p < 0.05, n = 3.
Figure 2
Figure 2
Characteristics of DIO mice fed with an HFD after 6 and 16 weeks (A) Body weights of mice fed with an HFD for 6 and 16 weeks. (B) Relative fold changes of miR-200c in gingiva and WAT in mice fed with an HFD for 6 weeks. (C and D) Relative transcript level changes of noggin, Zeb1, IL-6, and IL-8 in gingival tissues and WAT in mice fed with an HFD for 6 weeks. (E) Relative fold changes of miR-200c in gingiva and WAT in mice fed with an HFD for 16 weeks. (F and G) Relative transcript change of noggin, Zeb1, IL-6, and IL-8 in gingival tissues and WAT in mice fed with an HFD for 16 weeks. (H) Concentrations of IL-6 in blood serum in mice fed with an HFD for 16 weeks. (I) Blood glucose concentrations of a GTT test in mice fed with an HFD for 16 weeks. ∗p < 0.05 versus wild-type (WT), n = 3–9.
Figure 3
Figure 3
Characteristics of adipogenesis of hBMSCs on miR-200c expression (A) Microphotographs of hBMSCs with Oil Red O staining 3 weeks after adipogenic differentiation and control. (B) Relative transcript changes of noggin, Zeb1, LPL, PPAR-γ, and leptin of hBMSCs 1 week after adipogenic differentiation compared to controls. (C) Relative fold change of miR-200c hBMSCs 3 and 7 days after differentiation and controls. (D) Normalized fold changes of miR-200c expression in hBMSCs 3 days after treatment with PMIS-miR-200c. (E) Relative transcript changes of PPAR-γ, LPL, and noggin in adipogenic differentiated hBMSCs pretreated with PMIS-miR-200c. ∗p < 0.05, performed in triplicate.
Figure 4
Figure 4
Pathophysiological characteristics of Pg-LPS injection into the gingival sulcus between maxillary M1/M2 of obese mice after 16 weeks of being fed an HFD (A) μCT scan of maxillary bones on the palatal side of obese mice 2 weeks after receiving Pg-LPS at different concentrations. (B–D) Quantitative measurement of AB loss, BMD, and BV/TV at maxillary M1/M2 of mice. (E) Relative fold change of miR-200c in gingival tissues of mice with different treatments. (F and G) Relative transcript changes of IL-6, IL-8, and Zeb1 in gingiva and WAT of mice after different treatments. (H) Serum glucose concentration measured by a GTT test in mice with different treatment. ∗p < 0.05 versus PBS injection; n = 3–6.
Figure 5
Figure 5
Representative μCT scan and microphotographs of histological cross-sections of obese mice 4 weeks after receiving Pg-LPS with miR-200c treatment and controls (A) μCT images on the palatal side and cross-section of maxillary bones. (B) H&E-stained histological cross-section of mice after different treatments. AB, alveolar bone; arrow, granulation tissues; scale bar, 100 μm. (C) TRAP-stained histological cross-section of mice after different treatments. Arrow, activated osteoclasts; scale bar, 100 μm.
Figure 6
Figure 6
Quantitative measurements of the effectiveness of miR-200c on attenuating AB loss and systemic inflammation in obese mice with periodontitis (A–C) Quantitative μCT measurement of AB loss (A), BMD (B), and BV/TV (C) at maxillary M2/M3 of obese mice with Pg-LPS injection 4 weeks after treatment with miR-200c at different concentrations and controls. (D) Serum concentration of IL-6 in mice 4 weeks after different treatments. (E and F) Relative transcript changes of miR-200c, IL-6, and IL-8 in gingiva and WAT of mice with different treatments. (G) Serum glucose concentrations from a GTT test in mice 4 weeks after receiving different treatments. ∗p < 0.05 versus LPS-EV, n = 4–6.
Figure 7
Figure 7
Exosomal miR-200c on inflammation and adipogenesis (A) Relative fold change of miR-200c in serum exosomes isolated from mice receiving plasmid miR-200c injection in gingival tissues. p = 0.075, n = 3. (B) TEM image of exosomes isolated from HEPM cells with an overexpression of miR-200c and western blot using anti-CD63 and CD-9. (C) Relative fold changes of miR-200c in human ADSCs after treatment with exosomes isolated from HEPM cells with miR-200c overexpression and controls. (D) Relative transcript changes of IL-6, IL-8, and LPL in human ADSCs after treatment with exosomes isolated from HEPM cells with miR-200c overexpression and controls. ∗p < 0.05, performed in triplicate.
Figure 8
Figure 8
Effectiveness of IL-6 and LPS on miR-200c and Zeb1 (A and B) Relative fold changes of miR-200c expression in HEPM cells treated with IL-6 and LPS at different concentrations. (C and D) Relative transcript changes of Zeb1 in HEPM cells treated with IL-6 and Pg-LPS at different concentrations. ∗p < 0.05, performed in triplicate.
Figure 9
Figure 9
Potential roles of miR-200c in pathogenesis and treatment of PiOSs
See this image and copyright information in PMC

References

    1. Chapple I.L., Bouchard P., Cagetti M.G., Campus G., Carra M.C., Cocco F., Nibali L., Hujoel P., Laine M.L., Lingstrom P. Interaction of lifestyle, behaviour or systemic diseases with dental caries and periodontal diseases: consensus report of group 2 of the joint EFP/ORCA workshop on the boundaries between caries and periodontal diseases. J. Clin. Periodontol. 2017;44(Suppl 18):S39–S51. - PubMed
    1. Iwasaki M., Kimura Y., Ogawa H., Yamaga T., Ansai T., Wada T., Sakamoto R., Ishimoto Y., Fujisawa M., Okumiya K. Periodontitis, periodontal inflammation, and mild cognitive impairment: A 5-year cohort study. J. Periodontal Res. 2019;54:233–240. - PubMed
    1. Akram Z., Abduljabbar T., Abu Hassan M.I., Javed F., Vohra F. Cytokine Profile in Chronic Periodontitis Patients with and without Obesity: A Systematic Review and Meta-Analysis. Dis. Markers. 2016;2016:4801418. - PMC - PubMed
    1. Al-Rawi N.H., Shahid A.M. Oxidative stress, antioxidants, and lipid profile in the serum and saliva of individuals with coronary heart disease: is there a link with periodontal health? Minerva Stomatol. 2017;66:212–225. - PubMed
    1. Benguigui C., Bongard V., Ruidavets J.B., Sixou M., Chamontin B., Ferrières J., Amar J. Evaluation of oral health related to body mass index. Oral Dis. 2012;18:748–755. - PubMed

LinkOut - more resources